Companies › Luye Pharma Group
7 active drug programs in 8 registered trials: 4 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Neurology, Other, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lurbinectedin RNA polymerase II inhibitor; RNA-dependent transcription inhibitor | POLR2A | Phase 3 | Relapsed Small Cell Lung Cancer | Dec 2027 |
| LY01610 Topoisomerase I inhibitor (liposomal formulation) | TOP1 | Phase 3 | Relapsed Small Cell Lung Cancer | Jun 2028 |
| LY06006 RANKL inhibitor | TNFSF11 | Phase 3 | Osteoporosis, Postmenopausal | – |
| LY01021 | – | Phase 2 | Assisted Reproduction | – |
| LPM6690176 (also: LY01024) | – | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| LPM3770164 sustained-release tablet | – | Phase 1 | Tardive Dyskinesia (TD) | – |
| LY03020 | – | Phase 1 | Schizophrenia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05853354 | LY06006 | Phase 3 | Osteoporosis, Postmenopausal | Metabolic and endocrine | Jul 2025 |
| NCT07292233 | LY03020 | Phase 1 | Schizophrenia | Neurology | Aug 2025 |
| NCT06731868 | LPM3770164 sustained-release tablet | Phase 1 | Tardive Dyskinesia (TD) | Neurology | Oct 2025 |
| NCT07230652 | LY03020 | Phase 1 | Schizophrenia | Neurology | Dec 2025 |
| NCT07236476 | LY01021 | Phase 2 | Assisted Reproduction | Other | Dec 2025 |
| NCT06240546 | LPM6690176 (also: LY01024) | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT06496048 | Lurbinectedin | Phase 3 | Relapsed Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06128837 | LY01610 | Phase 3 | Relapsed Small Cell Lung Cancer | Oncology | Jun 2028 |
Merck & Co. (MSD) Daiichi Sankyo Gilead Sciences AstraZeneca Henan Genuine Biotech Senhwa Biosciences GSK Jiangsu Hansoh Pharmaceutical Qilu Pharmaceutical Amgen
AB Science Guangzhou Lupeng Pharmaceutical Company Shanghai Pharmaceuticals Holding Debiopharm International GE Healthcare
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.